Cardiff Oncology Inc
NASDAQ:CRDF
Cardiff Oncology Inc
Net Income (Common)
Cardiff Oncology Inc
Net Income (Common) Peer Comparison
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Cardiff Oncology Inc
NASDAQ:CRDF
|
Net Income (Common)
-$41.5m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-13%
|
|
Abbvie Inc
NYSE:ABBV
|
Net Income (Common)
$4.8B
|
CAGR 3-Years
2%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
2%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Net Income (Common)
$484m
|
CAGR 3-Years
17%
|
CAGR 5-Years
-39%
|
CAGR 10-Years
-20%
|
|
Amgen Inc
NASDAQ:AMGN
|
Net Income (Common)
$3.8B
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-2%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Net Income (Common)
$3.6B
|
CAGR 3-Years
10%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Net Income (Common)
$3.9B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
10%
|
CAGR 10-Years
26%
|
See Also
What is Cardiff Oncology Inc's Net Income (Common)?
Net Income (Common)
-41.5m
USD
Based on the financial report for Dec 31, 2023, Cardiff Oncology Inc's Net Income (Common) amounts to -41.5m USD.
What is Cardiff Oncology Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
-13%
Over the last year, the Net Income (Common) growth was -7%. The average annual Net Income (Common) growth rates for Cardiff Oncology Inc have been -22% over the past three years , -17% over the past five years , and -13% over the past ten years .